ArticleFrontiers in pharmacology2026
Association between terbutaline sulfate plus ambroxol hydrochloride and clinical outcomes, pulmonary function, and inflammatory biomarkers in elderly patients with acute exacerbation of chronic obstructive pulmonary disease.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are characterized by airflow limitation and marked airway/systemic inflammation, particularly in elderly patients. Objective: To evaluate the association between terbutaline sulfate plus ambroxol hydrochloride and clinical outcomes, pulmonary function, and inflammatory biomarkers in elderly patients with AECOPD. Methods: This single-center retrospective cohort study included hospitalized patients aged ≥60 years diagnosed with AECOPD between January 2021 and June 2023. According to the in-hospital treatment regimen recorded in the medical charts, patients were assigned to a control group receiving standard baseline treatment plus terbutaline sulfate or a combination group receiving ambroxol hydrochloride in addition to the control regimen. The primary endpoint was the change in forced expiratory volume in 1 s (FEV Results: A total of 123 patients were included (control, n = 58; combination, n = 65). After treatment, the combination group showed greater improvement in FEV Conclusion: In elderly patients with AECOPD, terbutaline sulfate combined with ambroxol hydrochloride was associated with greater improvements in pulmonary function, inflammatory and airway remodeling-related biomarkers, symptom relief, and length of hospital stay than terbutaline sulfate alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.